March 29, 2021


Biochip development: Strategic alignment to global best practices



Good afternoon, as we ramp up activities related to the development of Archer’s biochip, I wanted to provide shareholders with two important resources that help in providing some context to how the Company’s activity aligns nationally and globally.

Firstly, a publication from the Bulletin of the World Health Organization, titled “A guide to aid the selection of diagnostic tests”.

In the publication:

  • A six-step approach to overcoming the obstacles in selecting and implementing in vitro diagnostic tests is reported. This approach was derived from a review of the diagnostics literature, and from reputable organisations’ experience with implementing diagnostics programmes.
  • The challenges involved in each of the six steps are discussed, while also providing an outline of current problems with the quality assurance of tests.

This publication is a guide to the global challenges that exist in the development of diagnostic testing, and highlights areas of greatest importance and value-add to key end-use stakeholders.

Secondly, the Australian Government’s Medical Products National Manufacturing Priority Road Map.

The Road Map:

  • Recognises Australian medical products have the potential for global capability and capacity. The focus is on local manufacturing of advanced and high-value products using sophisticated processes.
  • Key growth opportunities include medical devices, including diagnostics, and data-driven digitally integrated products and platforms; these areas apply to Archer’s biochip development.

The Road Map provides an insight into areas of national strategic priority and describes opportunities for high-value growth over the next 2-5 years in medical product manufacturing and commercialisation in Australia.


Dr Mohammad Choucair, FRACI FRSN GAICD
Chief Executive Officer
Archer Materials Limited (ASX:AXE)

Click here to view the full commentary.